Imatinib

Category: pharmacological

Aliases: Gleevec, STI571

Pharmacological Mechanism

First-in-class targeted-cancer drug — competitive ATP-site inhibitor of BCR-ABL tyrosine kinase (chronic myeloid leukemia) plus c-Kit (GIST) and PDGFR. Transformed CML from a fatal disease into a chronic condition. CYP3A4 substrate + moderate inhibitor.

Half-Life (t½)

PO: 18h

Dosing Guidelines

• PO: Typical 400 mg (Range: 100–800 mg)

Target Organ Systems

• digestive
• immune-hematologic

Pathways It Modulates

• MAPK / ERK (RAS-RAF-MEK-ERK) cascade (inhibitor) — BCR-ABL / KIT / PDGFR (upstream RTK)
• PI3K / AKT signaling (inhibitor) — BCR-ABL / KIT / PDGFR upstream of PI3K
• Tyrosine kinase inhibition (inhibitor) — BCR-ABL + c-KIT + PDGFR

Chemical Identifiers

• PubChem CID: 5291
• Formula: C29H31N7O
• Molecular weight: 493.6 g/mol
• InChIKey: KTUFNOKKBVMGRW-UHFFFAOYSA-N
• SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5

References

• PMID 26189007